Page last updated: 2024-08-24

adenosine and Parkinson Disease

adenosine has been researched along with Parkinson Disease in 71 studies

Research

Studies (71)

Timeframe	Studies, this research(%)	All Research%
pre-1990	2 (2.82)	18.7374
1990's	3 (4.23)	18.2507
2000's	24 (33.80)	29.6817
2010's	19 (26.76)	24.3611
2020's	23 (32.39)	2.80

Authors

Authors	Studies
Ishibashi, K; Ishii, K; Ishiwata, K; Miura, Y; Toyohara, J; Wagatsuma, K	2
Medvedeva, MV; Muronetz, VI; Pozdyshev, DV; Zharikova, AA	1
Catarzi, D; Colotta, V; Francucci, B; Lambertucci, C; Marucci, G; Spinaci, A; Varano, F; Volpini, R	1
Borroto-Escuela, DO; Carlsson, J; Ciruela, F; Crans, RAJ; Fores-Pons, R; Fuxe, K; Lopez-Cano, M; Narváez, M; Romero-Fernandez, W; Taura, JJ	1
Airas, L; Helin, S; Joutsa, J; Parkkola, R; Rinne, JO; Rissanen, E; Tuisku, J; Waggan, I	1
Fathi, M; Hajibeygi, R; Jazi, K; Klegeris, A; McElhinney, A; Sayehmiri, F; Shool, S; Sodeifian, F; Tavasol, A; Tavirani, MR; Vakili, K; Yaghoobpoor, S	1
Cunha, RA; Gonçalves, FQ; Gonçalves, N; Matheus, FC; Oses, JP; Prediger, RD; Real, JI; Rial, D; Rodrigues, RJ; Silva, AC; Silva, HB; Tomé, ÂR	1
Han, YY; Huang, SY; Li, CH; Liu, L; Mai, ZF; Shang, YJ; Su, ZY; Zeng, ZW	1
Gu, L; He, J; Jin, S; Li, R; Peng, Y; Wei, L	1
Kerasidis, A; Nagle, B; Offit, M; Ozay, G; Pagan, F; Torres-Yaghi, Y; Zhang, I	1
Garcia, CP; Licht-Murava, A; Orr, AG	1
Jenner, P; Kanda, T; Mori, A	1
Franco, R; Labandeira-García, JL; Lanciego, JL; Muñoz, A; Navarro, G; Reyes-Resina, I; Rico, AJ; Rivas-Santisteban, R; Rodríguez-Pérez, AI	1
Agnati, LF; Guidolin, D; Marcoli, M; Maura, G; Tortorella, C	1
Chen, JF; Cunha, RA	1
Chen, C; Guo, J; Min, S; Pan, H; Qin, L; Shu, L; Sun, Q; Tang, B; Xu, Q; Yan, X; Zhong, J	1
He, H; Huang, Y; Qiu, X; Wang, J; Xiao, Y	1
Bansal, R; Chauhan, P; Kachler, S; Klotz, KN; Rohilla, S	1
Aradi, SD; Hauser, RA; LeWitt, PA; Rascol, O	1
Chen, JF; Schwarzschild, MA	1
Aradi, SD; Hauser, RA; Jenner, P; Mori, A	1
Ahmed, YR; Aziz, WM; Hamed, MAA; Khalil, WKB; Naser, AFA	1
Amalfitano, J; Jabeen, I; Kadri, H; Lai, YC; Le Duff, CS; Mehellou, Y; Miccoli, A; Muqit, MMK; Osgerby, L; Thornton, PJ; Tucker, JHR	1
Jamwal, S; Kumar, P	1
Fathalla, AM; Moustafa, AA; Soliman, AM	1
Chen, J; Duan, S; Gao, Z; Ge, Q; Guo, F; Guo, Z; Hu, Y; Lou, H; Mai, W; Meng, F; Zhang, B; Zhang, Z	1
Ali, S; Chen, X; Guo, M; Huang, H; Huang, Y; Qie, S; Wang, J; Wang, S; Yu, C; Zhang, L; Zheng, X	1
Borah, P; Deb, PK; Deka, S; Mailavaram, RP	1
Allen, EG; Armstrong, MJ; Jin, P; Jin, Y	1
Müller, T	2
Capuano, B; Jorg, M; Scammells, PJ	1
Borroto-Escuela, DO; Franco, R; Fuxe, K; Navarro, G	1
Boyle, CD; Chackalamannil, S; Cohen-Williams, ME; Greenlee, WJ; Higgins, GA; Lachowicz, JE; Lankin, CM; Neustadt, BR; Ng, K; Shah, U; Varty, GB; Zhang, H	1
Betz, AJ; Correa, M; Farrar, AM; Font, L; Hockemeyer, J; Ishiwari, K; Mingote, SM; Müller, CE; Salamone, JD	1
Chen, JF; Fredholm, BB; Hauser, R; Jenner, P; Morelli, M; Mori, A	1
Chung, EJ; Kim, BJ; Lee, GH; Lee, WY; Yoon, WT	1
Borea, PA; Casetta, I; Fazio, P; Gessi, S; Granieri, E; Granieri, G; Leung, E; MacLennan, S; Tosi, A; Varani, K; Vincenzi, F	1
Carta, AR; Kachroo, A; Morelli, M; Schwarzschild, MA	1
Che, PL; Du, J; Ha, B; Wang, Z; Yarema, KJ	1
Sperlágh, B; Vizi, ES	1
Burnstock, G; Fredholm, BB; Verkhratsky, A	1
Guo, KW; Hsu, LF; Tan, JK	1
Ahmed, I; Bose, SK; Brooks, DJ; Pavese, N; Ramlackhansingh, AF; Turkheimer, FE	1
Alexander, E; Beeler, JA; Bernandez, MS; Bernardez Sarria, MS; Frank, MJ; McDaid, J; McGehee, DS; Turkson, S; Zhuang, X	1
Górska, A; Gołembiowska, K; Kamińska, K; Noworyta-Sokołowska, K; Wardas, J	1
Aceves, J; Barajas, C; Erlij, D; Florán, B; Florán, L	1
Morelli, M	1
Fredholm, BB; Svenningsson, P	1
Mori, A; Shindou, T	1
Chen, JF	1
Agnati, LF; Ferré, S; Franco, R; Fuxe, K; Hockemeyer, J; Leo, G; Lluis, C; Martínez, E; Vergoni, AV	1
Cristalli, G; Morelli, M; Pinna, A; Volpini, R	1
Agnati, L; Antonelli, T; Ferraro, L; Fuxe, K; Mazzoni, E; Tanganelli, S; Tomasini, MC	1
Cacciari, B; Cristalli, G; Dal Ben, D; Lambertucci, C; Moro, S; Spalluto, G; Volpini, R	1
Chern, Y; Franco, R; Fredholm, BB; Sitkovsky, M	1
Boison, D	1
Pamplona, FA; Prediger, RD; Takahashi, RN	1
Asaad, W; Eskandar, E	1
Ramkumar, V; Toth, LA; Xie, X	1
Adami, M; Bertorelli, R; Ferri, C; Ongini, E	1
Ikeda, K; Jackson, MJ; Jenner, PG; Kanda, T; Kase, H; Koga, K; Kurokawa, M; Kuwana, Y; Ochi, M; Pearce, RK; Shiozaki, S; Smith, LA	1
Camp, DM; Harel, E; Juneau, PL; LeWitt, PA; Loeffler, DA	1
Ferré, S; Fuxe, K; Müller, CE; Popoli, P; Strömberg, I	1
Silkis, I	1
Sil'kis, IG	1
Kase, H	1
Martinez-Mir, MI; Palacios, JM; Probst, A	1
Ceccato, S; Passeri, M	1
Lipinski, J; Matthysse, S; Shih, V	1

Reviews

32 review(s) available for adenosine and Parkinson Disease

Article	Year
A Current medicinal chemistry, 2022, 08-06, Volume: 29, Issue:28 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Humans; Neuroprotective Agents; Parkinson Disease; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A	2022
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis. Frontiers in immunology, 2022, Volume: 13 Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleacetic Acid; Kynurenic Acid; Kynurenine; NAD; Niacinamide; Parkinson Disease; Tryptophan	2022
Effects of adenosine A International review of neurobiology, 2023, Volume: 170 Topics: Adenosine; Animals; Brain Injuries; Cognition; Cognitive Dysfunction; Humans; Parkinson Disease	2023
Adenosine A Progress in molecular biology and translational science, 2020, Volume: 169 Topics: Adenosine; Allosteric Site; Animals; Astrocytes; Central Nervous System; Computational Biology; Dopamine; Humans; Mice; Neurons; Parkinson Disease; Protein Binding; Protein Conformation; Protein Multimerization; Receptor, Adenosine A2A; Receptors, Dopamine D2; Schizophrenia; Signal Transduction	2020
The belated US FDA approval of the adenosine A Purinergic signalling, 2020, Volume: 16, Issue:2 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Humans; Parkinson Disease; Purines; Receptor, Adenosine A2A; United States; United States Food and Drug Administration	2020
Do caffeine and more selective adenosine A Parkinsonism & related disorders, 2020, Volume: 80 Suppl 1 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Disease Models, Animal; Humans; Neuroprotective Agents; Parkinson Disease; Receptor, Adenosine A2A	2020
Istradefylline - a first generation adenosine A Expert review of neurotherapeutics, 2021, Volume: 21, Issue:3 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Humans; Parkinson Disease; Purines	2021
Insight Into the Emerging Role of Striatal Neurotransmitters in the Pathophysiology of Parkinson's Disease and Huntington's Disease: A Review. Current neuropharmacology, 2019, Volume: 17, Issue:2 Topics: Acetylcholine; Adenosine; Animals; Basal Ganglia; Cannabinoids; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Huntington Disease; Neuropeptides; Parkinson Disease; Synaptic Transmission	2019
Adenosine role in brain functions: Pathophysiological influence on Parkinson's disease and other brain disorders. Pharmacological reports : PR, 2018, Volume: 70, Issue:4 Topics: Adenosine; Brain Diseases; Caffeine; Dopamine; Humans; Parkinson Disease	2018
P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future. Current pharmaceutical design, 2019, Volume: 25, Issue:26 Topics: Adenosine; Asthma; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Ligands; Neoplasms; Parkinson Disease; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Pyrazoles; Receptors, Purinergic P1	2019
Diverse and dynamic DNA modifications in brain and diseases. Human molecular genetics, 2019, 11-21, Volume: 28, Issue:R2 Topics: Adenosine; Alzheimer Disease; Animals; Ataxia; Brain; Chromatin; Cytosine; DNA; DNA Methylation; Epigenesis, Genetic; Histones; Humans; Mice; Neurodegenerative Diseases; Parkinson Disease	2019
Suitability of the adenosine antagonist istradefylline for the treatment of Parkinson's disease: pharmacokinetic and clinical considerations. Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:8 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Blood-Brain Barrier; Disease Models, Animal; Dopamine Agonists; Dyskinesias; Half-Life; Humans; Levodopa; Parkinson Disease; Purines; Treatment Outcome	2013
The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease. Current medicinal chemistry, 2014, Volume: 21, Issue:27 Topics: Adenosine; Animals; Dopamine; Drug Discovery; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Parkinson Disease; Receptor, Adenosine A2A; Receptors, Dopamine D2	2014
Purinergic signaling in Parkinson's disease. Relevance for treatment. Neuropharmacology, 2016, Volume: 104 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Corpus Striatum; Humans; Parkinson Disease; Purine Nucleotides; Purines; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Signal Transduction; Triazoles	2016
Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism & related disorders, 2008, Volume: 14 Suppl 2 Topics: Adenosine; Animals; Disease Models, Animal; Dopamine; Humans; Locomotion; Parkinson Disease; Tremor	2008
Adenosine, adenosine A 2A antagonists, and Parkinson's disease. Parkinsonism & related disorders, 2009, Volume: 15, Issue:6 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Clinical Trials as Topic; Humans; Parkinson Disease; Purines; Receptors, Purinergic P1	2009
Pathophysiological roles for purines: adenosine, caffeine and urate. Progress in brain research, 2010, Volume: 183 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Caffeine; Dopamine; Humans; Neuroprotective Agents; Parkinson Disease; Purines; Receptor, Adenosine A2A; Uric Acid	2010
The role of extracellular adenosine in chemical neurotransmission in the hippocampus and Basal Ganglia: pharmacological and clinical aspects. Current topics in medicinal chemistry, 2011, Volume: 11, Issue:8 Topics: Adenosine; Adenosine Triphosphate; Animals; Basal Ganglia; Extracellular Space; Gene Expression; Hippocampus; Humans; Ischemia; Mice; Nerve Net; Neuroglia; Neurons; Neurotransmitter Agents; Parkinson Disease; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Receptors, Purinergic P1; Synaptic Transmission	2011
Adenosine and ATP receptors in the brain. Current topics in medicinal chemistry, 2011, Volume: 11, Issue:8 Topics: Adenosine; Adenosine Triphosphate; Animals; Brain; Dogs; Epilepsy; Female; Gene Expression; Humans; Ischemia; Mice; Neuralgia; Neuroglia; Neurons; Neurotransmitter Agents; Parkinson Disease; Rabbits; Rats; Receptors, Purinergic P1; Receptors, Purinergic P2; Synaptic Transmission	2011
Adenosine A2A antagonists: potential preventive and palliative treatment for Parkinson's disease. Experimental neurology, 2003, Volume: 184, Issue:1 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Humans; Neuroprotective Agents; Palliative Care; Parkinson Disease; Parkinson Disease, Secondary; Rats	2003
Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Humans; Mice; Nerve Tissue Proteins; Parkinson Disease; Phosphoproteins; Phosphorylation; Pyrimidines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Signal Transduction; Triazoles	2003
The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. Drug news & perspectives, 2003, Volume: 16, Issue:9 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Brain; Caffeine; Dopamine; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptor, Adenosine A2A; Treatment Failure	2003
Aspects of the general biology of adenosine A2A signaling. Progress in neurobiology, 2007, Volume: 83, Issue:5 Topics: Adenosine; Animals; Dimerization; Encephalitis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia, Brain; Parkinson Disease; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Signal Transduction	2007
Adenosine as a neuromodulator in neurological diseases. Current opinion in pharmacology, 2008, Volume: 8, Issue:1 Topics: Adenosine; Adenosine Kinase; Alzheimer Disease; Animals; Brain Diseases; Brain Ischemia; Epilepsy; Humans; Huntington Disease; Pain; Parkinson Disease; Schizophrenia; Synaptic Transmission	2008
Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Frontiers in bioscience : a journal and virtual library, 2008, Jan-01, Volume: 13 Topics: Adenosine; Alzheimer Disease; Animals; Attention Deficit Disorder with Hyperactivity; Cognition Disorders; Disease Models, Animal; Humans; Learning; Memory; Parkinson Disease; Purinergic P1 Receptor Antagonists; Rats; Rats, Inbred SHR; Receptors, Purinergic P1	2008
Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. Comparative medicine, 2007, Volume: 57, Issue:6 Topics: Adenosine; Animals; Behavior, Animal; Caffeine; Corpus Striatum; Dopamine; Humans; Locomotion; Models, Biological; Parkinson Disease; Parkinsonian Disorders; Receptors, Dopamine; Receptors, Purinergic P1; Rodentia; Signal Transduction	2007
Adenosine A2A receptors and neuroprotection. Annals of the New York Academy of Sciences, 1997, Oct-15, Volume: 825 Topics: Adenosine; Animals; Brain; Brain Diseases; Brain Ischemia; Dopamine; Humans; Neuroprotective Agents; Parkinson Disease; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Purinergic P1; Seizures	1997
Antiparkinsonian activity of adenosine A2A antagonists in experimental models. Advances in neurology, 1999, Volume: 80 Topics: Adenosine; Antiparkinson Agents; Humans; Motor Activity; Parkinson Disease; Phenethylamines; Purinergic P1 Receptor Antagonists; Receptors, Purinergic P1; Xanthines	1999
The cortico-basal ganglia-thalamocortical circuit with synaptic plasticity. II. Mechanism of synergistic modulation of thalamic activity via the direct and indirect pathways through the basal ganglia. Bio Systems, 2001, Volume: 59, Issue:1 Topics: Adenosine; Basal Ganglia; Cerebral Cortex; Dopamine; Humans; Huntington Disease; Long-Term Potentiation; Models, Neurological; Movement Disorders; Neural Pathways; Parkinson Disease; Signal Transduction; Synapses; Thalamus	2001
[Mechanisms of effects of adenosine and dopamine on modification of synapses in striato-nigral and striato-pallidal neurons]. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2001, Volume: 87, Issue:2 Topics: Adenosine; Animals; Dopamine; Dopamine Agonists; Dopamine Antagonists; Globus Pallidus; Huntington Disease; Motor Activity; Parkinson Disease; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, Purinergic P1; Substantia Nigra; Synapses; Synaptic Transmission	2001
Non-dopaminergic drug treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:4 Topics: Adenosine; Adrenergic alpha-Antagonists; Body Weight; Cholinergic Antagonists; Homocysteine; Humans; Levodopa; Methionine; N-Methylaspartate; Parkinson Disease; Piperidines; Serotonin Receptor Agonists	2001
New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia. Bioscience, biotechnology, and biochemistry, 2001, Volume: 65, Issue:7 Topics: Adenosine; Animals; Basal Ganglia; gamma-Aminobutyric Acid; Humans; Models, Neurological; Neurotransmitter Agents; Parkinson Disease; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Receptor, Adenosine A2A; Receptors, Purinergic P1; Synaptic Transmission	2001

Trials

1 trial(s) available for adenosine and Parkinson Disease

Article	Year
MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Movement disorders : official journal of the Movement Disorder Society, 2009, Aug-15, Volume: 24, Issue:11 Topics: 3-Iodobenzylguanidine; Adenosine; Aged; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Galvanic Skin Response; Heart; Heart Rate; Humans; Iodine Radioisotopes; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Respiration; Sensitivity and Specificity; Sympathetic Fibers, Postganglionic; Tomography, Emission-Computed, Single-Photon; Valsalva Maneuver	2009

Article

Year

MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy.

Movement disorders : official journal of the Movement Disorder Society, 2009, Aug-15, Volume: 24, Issue:11

Topics: 3-Iodobenzylguanidine; Adenosine; Aged; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Galvanic Skin Response; Heart; Heart Rate; Humans; Iodine Radioisotopes; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Parkinsonian Disorders; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Respiration; Sensitivity and Specificity; Sympathetic Fibers, Postganglionic; Tomography, Emission-Computed, Single-Photon; Valsalva Maneuver

2009

Other Studies

38 other study(ies) available for adenosine and Parkinson Disease

Article	Year
Adenosine A Movement disorders : official journal of the Movement Disorder Society, 2022, Volume: 37, Issue:4 Topics: Adenosine; Caffeine; Coffee; Humans; Parkinson Disease; Receptor, Adenosine A2A	2022
Differential Analysis of A-to-I mRNA Edited Sites in Parkinson's Disease. Genes, 2021, 12-22, Volume: 13, Issue:1 Topics: Adenosine; Aged; Humans; Inosine; Male; Mitochondria; Parkinson Disease; Prefrontal Cortex; Proteome; RNA; RNA Editing; RNA, Messenger; Sequence Analysis, RNA; Transcriptome	2021
The mGlu Molecular neurobiology, 2022, Volume: 59, Issue:10 Topics: Adenosine; Animals; Catalepsy; Dopamine; Haloperidol; HEK293 Cells; Humans; Mice; Parkinson Disease; Protein Subunits; Rats; Receptor, Adenosine A2A; Receptors, Dopamine D2	2022
Adenosine A Journal of neurology, 2023, Volume: 270, Issue:1 Topics: Adenosine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Receptor, Adenosine A2A	2023
Increased ATP Release and Higher Impact of Adenosine A Molecular neurobiology, 2023, Volume: 60, Issue:3 Topics: Adenosine; Adenosine Triphosphate; Animals; Humans; Long-Term Potentiation; Mice; Neuronal Plasticity; Parkinson Disease; Rats	2023
Cordycepin improved the cognitive function through regulating adenosine A Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023, Volume: 110 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine; Animals; Cognition; Disease Models, Animal; Mice; Mice, Inbred C57BL; Parkinson Disease	2023
Exercise attenuates neuronal degeneration in Parkinson's disease rat model by regulating the level of adenosine 2A receptor. Folia neuropathologica, 2023, Volume: 61, Issue:2 Topics: Adenosine; Animals; Cytokines; Parkinson Disease; Phenethylamines; Rats	2023
Adenosine A International review of neurobiology, 2023, Volume: 170 Topics: Acetylcholine; Adenosine; Dopamine; Dopamine Agonists; Humans; Parkinson Disease	2023
How and why the adenosine A International review of neurobiology, 2023, Volume: 170 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Basal Ganglia; Brain; Dopamine; Humans; Parkinson Disease; Receptor, Adenosine A2A	2023
Boolean analysis shows a high proportion of dopamine D Neurobiology of disease, 2023, Volume: 188 Topics: Adenosine; Animals; Corpus Striatum; Dopamine; Medium Spiny Neurons; Parkinson Disease; Primates; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; Receptors, Dopamine D1; Receptors, Purinergic P1; Reproducibility of Results	2023
Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease. Neurobiology of aging, 2020, Volume: 93 Topics: Adenosine; Aged; Aged, 80 and over; Asian People; Brain; Cell Cycle Proteins; Female; Genetic Association Studies; Genetic Variation; Humans; Male; Methyltransferases; Middle Aged; Parkinson Disease; Risk; RNA Processing, Post-Transcriptional; RNA Splicing Factors	2020
Genome-wide identification of m Neuroscience letters, 2020, 10-15, Volume: 737 Topics: Adenosine; AlkB Homolog 5, RNA Demethylase; Databases, Genetic; Gene Expression; Gene Expression Regulation; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Parkinson Disease; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Quantitative Trait Loci	2020
A New Series of 1,3-Dimethylxanthine Based Adenosine A Current drug discovery technologies, 2021, Volume: 18, Issue:5 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Molecular Docking Simulation; Parkinson Disease; Rats; Receptor, Adenosine A2A; Structure-Activity Relationship; Theophylline	2021
Adenosine A Movement disorders : official journal of the Movement Disorder Society, 2021, Volume: 36, Issue:1 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Antiparkinson Agents; Humans; Parkinson Disease; Purines; Receptor, Adenosine A2A	2021
The challenge of developing adenosine A Parkinsonism & related disorders, 2020, Volume: 80 Suppl 1 Topics: Adenosine; Animals; Antiparkinson Agents; Benzothiazoles; Humans; Levodopa; Parkinson Disease; Purines	2020
Parkinsonism-like Disease Induced by Rotenone in Rats: Treatment Role of Curcumin, Dopamine Agonist and Adenosine A Current aging science, 2022, 02-03, Volume: 15, Issue:1 Topics: Adenosine; Aged; Animals; Curcumin; Disease Models, Animal; Dopamine Agonists; Humans; Inflammation Mediators; Mice; Neuroprotective Agents; Parkinson Disease; Parkinsonian Disorders; Rats; Receptor, Adenosine A2A; Rotenone	2022
Kinetin Riboside and Its ProTides Activate the Parkinson's Disease Associated PTEN-Induced Putative Kinase 1 (PINK1) Independent of Mitochondrial Depolarization. Journal of medicinal chemistry, 2017, 04-27, Volume: 60, Issue:8 Topics: Adenosine; Animals; Carbon-13 Magnetic Resonance Spectroscopy; Humans; Kinetin; Mitochondria; Parkinson Disease; Protein Kinases; Proton Magnetic Resonance Spectroscopy; Spectrometry, Mass, Electrospray Ionization	2017
CD73-derived adenosine controls inflammation and neurodegeneration by modulating dopamine signalling. Brain : a journal of neurology, 2019, 03-01, Volume: 142, Issue:3 Topics: 5'-Nucleotidase; Adenosine; Animals; Disease Models, Animal; Dopamine; Dopaminergic Neurons; GPI-Linked Proteins; Inflammation; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microglia; Neurodegenerative Diseases; Parkinson Disease; Receptor, Adenosine A2A; Signal Transduction	2019
Down-Regulation of m6A mRNA Methylation Is Involved in Dopaminergic Neuronal Death. ACS chemical neuroscience, 2019, 05-15, Volume: 10, Issue:5 Topics: Adenosine; Animals; Apoptosis; Brain; Cell Death; Disease Models, Animal; Dopaminergic Neurons; Down-Regulation; Epigenesis, Genetic; Male; Methylation; Oxidopamine; Parkinson Disease; PC12 Cells; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sympatholytics	2019
Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists. Bioorganic & medicinal chemistry letters, 2008, Jul-15, Volume: 18, Issue:14 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Area Under Curve; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Design; Hydrogen-Ion Concentration; Models, Chemical; Parkinson Disease; Pyrimidines; Rats; Solubility; Triazoles; Water	2008
A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2010, Volume: 24, Issue:2 Topics: Adenosine; Aged; Aged, 80 and over; Animals; Autopsy; Cyclic AMP; Dopamine; Female; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Parkinson Disease; PC12 Cells; Putamen; Rats; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptor, Adenosine A3; Receptors, Dopamine D2; RNA, Messenger; Tumor Necrosis Factor-alpha	2010
Static magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385. PloS one, 2010, Nov-08, Volume: 5, Issue:11 Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Adenosine Triphosphate; Analysis of Variance; Animals; Blotting, Western; Calcium; Cell Proliferation; Cyclic AMP; Iron; Magnetic Field Therapy; Magnetics; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neurites; Parkinson Disease; PC12 Cells; Phenethylamines; Phosphorylation; Rats; Receptor, Adenosine A2A; Triazines; Triazoles	2010
Palpitations and narrow-complex tachycardia. Singapore medical journal, 2011, Volume: 52, Issue:4 Topics: Adenosine; Diagnosis, Differential; Dyspnea; Electric Countershock; Electrocardiography; Humans; Hypertension; Male; Middle Aged; Parkinson Disease; Tachycardia; Treatment Outcome	2011
Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Neurology, 2011, May-24, Volume: 76, Issue:21 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Aged; Animals; Antiparkinson Agents; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Receptor, Adenosine A2A	2011
A role for dopamine-mediated learning in the pathophysiology and treatment of Parkinson's disease. Cell reports, 2012, Dec-27, Volume: 2, Issue:6 Topics: Adenosine; Animals; Behavior, Animal; Dopamine; Dopamine D2 Receptor Antagonists; Learning; Mice; Mice, Transgenic; Motor Activity; Parkinson Disease; Receptors, Dopamine D2; Signal Transduction	2012
Effects of adenosine receptor antagonists on the in vivo LPS-induced inflammation model of Parkinson's disease. Neurotoxicity research, 2013, Volume: 24, Issue:1 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Corpus Striatum; Dopamine; Dopaminergic Neurons; Glutamic Acid; Hydroxyl Radical; Inflammation; Lipopolysaccharides; Male; Microinjections; Parkinson Disease; Purines; Rats; Receptor, Adenosine A2A	2013
Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. Neuroscience, 2002, Volume: 115, Issue:3 Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenosine; Animals; Calcium Signaling; Dopamine Agonists; Dopamine Antagonists; gamma-Aminobutyric Acid; Male; Motor Activity; Neural Inhibition; Neurons; Organ Culture Techniques; Parkinson Disease; Potassium; Rats; Rats, Wistar; Receptors, Dopamine D1; Receptors, Purinergic P1; Substantia Nigra; Synaptic Transmission; Tritium; Xanthines	2002
Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Corpus Striatum; gamma-Aminobutyric Acid; Globus Pallidus; In Vitro Techniques; Neurons; Parkinson Disease; Patch-Clamp Techniques; Phenethylamines; Rats; Receptor, Adenosine A2A; Synaptic Transmission	2003
Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain research bulletin, 2004, Aug-30, Volume: 64, Issue:2 Topics: Adenosine; Adenosine A2 Receptor Agonists; Analysis of Variance; Animals; Antiparkinson Agents; Apomorphine; Cell Count; Corpus Striatum; Disease Models, Animal; Dopamine Agonists; Drug Therapy, Combination; Dyskinesias; Immunohistochemistry; Levodopa; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Rats; Rats, Sprague-Dawley; Stereotyped Behavior; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase	2004
New adenosine A2A receptor antagonists: actions on Parkinson's disease models. European journal of pharmacology, 2005, Apr-11, Volume: 512, Issue:2-3 Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Binding, Competitive; Catalepsy; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Drug Synergism; Levodopa; Male; Molecular Structure; Parkinson Disease; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Tritium	2005
Experimental studies and theoretical aspects on A2A/D2 receptor interactions in a model of Parkinson's disease. Relevance for L-dopa induced dyskinesias. Journal of the neurological sciences, 2006, Oct-25, Volume: 248, Issue:1-2 Topics: Adenosine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Chromatography, High Pressure Liquid; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Drug Interactions; Electrochemistry; gamma-Aminobutyric Acid; Globus Pallidus; Male; Microdialysis; Models, Biological; Oxidopamine; Parkinson Disease; Phenethylamines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Dopamine D2	2006
Highlights on the development of A(2A) adenosine receptor agonists and antagonists. ChemMedChem, 2007, Volume: 2, Issue:3 Topics: Adenosine; Adenosine A2 Receptor Agonists; Adenosine A2 Receptor Antagonists; Drug Design; Humans; Parkinson Disease; Receptors, G-Protein-Coupled; Spinal Cord Injuries; Structure-Activity Relationship	2007
The movers and shakers of deep brain stimulation. Nature medicine, 2008, Volume: 14, Issue:1 Topics: Adenosine; Animals; Cerebellum; Deep Brain Stimulation; Humans; Mice; Models, Biological; Parkinson Disease; Thalamus; Tremor	2008
Purine-induced alterations of dopamine metabolism in rat pheochromocytoma PC12 cells. Brain research bulletin, 2000, Volume: 52, Issue:6 Topics: Adenine; Adenosine; Animals; Disease Models, Animal; Dopamine; Guanine; Guanosine; Hypoxanthine; Neostriatum; Neural Pathways; Neurons; Parkinson Disease; PC12 Cells; Purines; Rats; Substantia Nigra; Uric Acid; Xanthine	2000
Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine-denervated striatum. The European journal of neuroscience, 2000, Volume: 12, Issue:11 Topics: Adenosine; Animals; Corpus Striatum; Denervation; Disease Models, Animal; Dopamine; Functional Laterality; Humans; Male; Oxidopamine; Parkinson Disease; Phenethylamines; Purinergic P1 Receptor Antagonists; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Dopamine D2; Receptors, Purinergic P1; Reference Values	2000
Adenosine A2 receptors: selective localization in the human basal ganglia and alterations with disease. Neuroscience, 1991, Volume: 42, Issue:3 Topics: Adenosine; Aged; Aged, 80 and over; Animals; Basal Ganglia; Corpus Striatum; Female; Guinea Pigs; Humans; Huntington Disease; Male; Middle Aged; Nerve Degeneration; Organ Specificity; Oxidopamine; Parkinson Disease; Quinolinic Acid; Quinolinic Acids; Receptors, Purinergic	1991
[Significance of transmethylation and S-adenosylmethionine (SAM) in the management of Parkinson's disease with L-dopa]. Minerva medica, 1972, Apr-21, Volume: 63, Issue:30 Topics: Adenosine; Aged; Brain; Digestive System; Dihydroxyphenylalanine; Feeding and Eating Disorders; Female; Gastrointestinal Diseases; Humans; Injections, Intramuscular; Injections, Intravenous; Kidney; Male; Methionine; Methylation; Nausea; Parkinson Disease; S-Adenosylmethionine; Vomiting	1972
L-dopa and S-adenosylmethionine. Clinica chimica acta; international journal of clinical chemistry, 1971, Volume: 35, Issue:1 Topics: Adenosine; Carbon Isotopes; Dihydroxyphenylalanine; Humans; Methionine; Parkinson Disease; S-Adenosylmethionine; Time Factors; Tritium	1971